Genitourinary Cancer

Top Story

Adverse skin reactions can occur months after anti-PD-1 treatment

July 18, 2018
In the Journals Plus

‘Simple’ model predicts risk for cancer-related venous thromboembolism

July 17, 2018
A clinical prediction model that used tumor-site category and D-dimer as the only variables accurately predicted risk for venous thromboembolism among patients with…
Meeting News

Nivolumab prior to surgery appears safe, effective in metastatic renal cell carcinoma

July 13, 2018
CHICAGO — Nivolumab plus or minus bevacizumab or ipilimumab prior to surgery appeared safe and demonstrated promising clinical activities in patients with…
Meeting News

Alternative chemotherapy dosing schedule appears safe in patients with bladder cancer

July 12, 2018
CHICAGO — A “split” schedule of cisplatin-based chemotherapy conferred lower pathologic response rates compared with a convention schedule in patients…
More Headlines »

Decisions, Decisions: Differentiating Checkpoint Inhibitors for Bladder Cancer

This activity is supported by an educational grant from Merck & Co., Inc.

The integration of immune checkpoint inhibitors into treatment algorithms for patients with bladder cancer who have…
More »
Meeting News

VIDEO: Geographic location plays role in renal cell carcinoma outcomes

November 3, 2017
More »
Resource Centers
ASCO Annual Meeting

ASCO Annual Meeting


Immune Checkpoint Inhibitors for Genitourinary Cancers: Practice Essential for Community Oncologists and Advanced Practice Providers

This activity is supported by an educational grant from Merck & Co., Inc.

For many years, the mainstay of initial treatment for metastatic bladder cancer has been chemotherapy. However…
More »